Lara Sullivan, MD, President and Founder at SpringWorks Therapeutics discusses the mechanism of action of Senicapoc (a Gardos channel blocker), an emerging treatment for Hereditary Xerocytosis, a genetic disorder in which red blood cells become dehydrated due to loss of potassium and cell water.